Zusammenfassung
Für die Schmerzbehandlung werden in erster Linie Opioide und nichtopioide Analgetika eingesetzt. Die nichtopioiden Analgetika wirken zusätzlich antipyretisch, einige auch entzündungshemmend. In manchen Fällen bereitet es Schwierigkeiten, eine eindeutige Trennung von Analgetika gegenüber den Antirheumatika und Antiphlogistika vorzunehmen. So wird Acetylsalicylsäure besonders in Deutschland vorzugsweise zur Behandlung von Schmerzen eingesetzt. Sie wirkt aber in höheren Dosen auch antiphlogistisch. Seit mehreren Jahren werden die nichtsteroidalen Antiphlogistika Ibuprofen, Naproxen und Diclofenac in geringerer Dosis als rezeptfreie Schmerzmittel verwendet.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Allan L, Richarz U, Simpson K, Slappendel R (2005): Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine 30: 2484–2490.
Arzneimittelkommission der deutschen Ärzteschaft (1986): Bundesgesundheitsamt schrankt Anwendungsgebiet von Metamizol-haltigen Monopraparaten ein. Dtsch Ärztebl 83: 3267.
Arzneimittelkommission der deutschen Ärzteschaft (2007): Empfehlungen zur Therapie von Tumorschmerzen. AVP-Sonderheft Therapieempfehlungen, 3. Auflage. Internet: www.akdae.de/35/10/66-Tumorschmerzen-2007-3Auflage.pdf
Budd K (1990): Experience with partial antagonists in the treatment of cancer pain. In: Doyle D (Ed). Opioids in the treatment of cancer pain. Royal Society of Medicine, International Congress and Symposium Series No. 146, pp. 51–54.
Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M (2005): Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 94: 825–834.
Drover DR, Angst MS, Valle M, Ramaswamy B, Naidu S, Stanski DR, Verotta D (2002): Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 97: 827–836.
Frampton JE (2010): Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain. Drugs 70: 1719–1743.
Fürlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E (2006): Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 174: 1589–1594.
Hanks GW, De Conno F, Cherny N et al (Expert Working Group of the Research Network of the European Association for Palliative Care) (2001): Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84: 587–593.
Jacox A, Carr DB, Payne R et al (Agency for Health Care Policy and Research (AHCPR) Pharmacological Management) (1994): Recommendations. In: Management of cancer pain. Clinical Practice Guideline No 9. U.S. Department of Health and Human Services, Public Health Service, AHCPR Publication No 94–0592, March, Rockville.
Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M, Ruckes C, Wirz S, Fleischer W, Reimer K (2009a): A randomised controlled trial with prolongedrelease oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 13: 56–64.
Meissner W, Mueller-Lissner S, Nadstawek J, Hopp M, Ruckes C, Wirz S, Fleischer W, Reimer K, Leyendecker P (2009b): Dr. Meissner and colleagues reply to the Letter to the Editor from Andrew Wilcock entitled ‘Prolonged-release naloxone can cause systemic opioid withdrawal’. Eur J Pain 13: 1002–1003.
Radbruch L, Elsner F (2005): Palliative Schmerztherapie, Cannabinoide. Internist 46: 1105–1114.
Ripamonti C, Fagnoni E, Campa T, Brunelli C, De Conno F (2006): Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Support Care Cancer 14: 400–407.
Quigley C (2002): Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev. 2002 (1): CD003447.
Szelenyi I, Nickel B, Borbe HO, Brune K (1989): Mode of antinociceptive action of flupirtine in the rat. Br J Pharmacol 97: 835–842.
The Pain Society (2004): Recommendations for the appropriate use of opioids for persistent non-cancer pain. A consensus statement prepared on behalf of the Pain Society, the Royal College of Anaesthetists, the Royal College of General Practitioners and the Royal College of Psychiatrists. March 2004. Internet: www.britishpainsociety.org/pdf/opioids_doc_2004.pdf.
Wilcock A (2009): Prolonged-release naloxone can cause systemic opioid withdrawal. Eur J Pain 13: 1001 (2009).
World Health Organization (WHO) (1986): Cancer Pain Relief. World Health Organization Publications, Geneva, Switzerland.
World Health Organization (WHO) (1996): Cancer pain relief, 2nd edn. World Health Organization Publications, Geneva, Switzerland.
Zhang WY, Po AL (1996): Analgesic efficacy of paracetamol and its combination with codeine and caffeine in surgical pain – a metaanalysis. J Clin Pharm Ther 21: 261–282.
Zhang WY, Po AL (1997): Do codeine and caffeine enhance the analgesic effect of aspirin? A systematic overview. J Clin Pharm Ther 22: 79–97.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Böger, R.H., Schmidt, G. (2011). Analgetika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2011. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-21992-4_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-21992-4_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-21991-7
Online ISBN: 978-3-642-21992-4
eBook Packages: Medicine (German Language)